Exenatide Pen Injector [Bydureon] ( DrugBank: Exenatide )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 17 | 多系統萎縮症 | 1 |
17. 多系統萎縮症
臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04431713 (ClinicalTrials.gov) | September 16, 2020 | 29/5/2020 | Exenatide Once-weekly as a Treatment for Multiple System Atrophy | An Open Label, Single Site, 48 Week, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exenatide Once-weekly in the Treatment of Patients With Multiple System Atrophy | Multiple System Atrophy | Drug: Exenatide Pen Injector [Bydureon] | University College, London | NULL | Recruiting | 30 Years | 80 Years | All | 50 | Phase 2 | United Kingdom |